Chandran, Smita S. http://orcid.org/0000-0001-9266-6878
Ma, Jiaqi http://orcid.org/0000-0002-6298-0193
Klatt, Martin G. http://orcid.org/0000-0001-8703-7305
Dündar, Friederike http://orcid.org/0000-0002-2301-112X
Bandlamudi, Chaitanya
Razavi, Pedram http://orcid.org/0000-0003-4236-0576
Wen, Hannah Y.
Weigelt, Britta http://orcid.org/0000-0001-9927-1270
Zumbo, Paul
Fu, Si Ning
Banks, Lauren B.
Yi, Fei
Vercher, Enric
Etxeberria, Inaki http://orcid.org/0000-0003-2713-0836
Bestman, Watchain D.
Da Cruz Paula, Arnaud
Aricescu, Ilinca S.
Drilon, Alexander http://orcid.org/0000-0001-6806-9061
Betel, Doron http://orcid.org/0000-0002-8006-7752
Scheinberg, David A.
Baker, Brian M.
Klebanoff, Christopher A. http://orcid.org/0000-0001-9645-3896
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R37 CA259177, AI129543)
Damon Runyon Cancer Research Foundation (CI-96-18)
Cancer Research Institute (CRI3176)
Article History
Received: 2 April 2021
Accepted: 16 March 2022
First Online: 28 April 2022
Competing interests
: S.S.C. and C.A.K. are inventors of the TCR discovery platform and the <i>PIK3CA</i> public NeoAg TCRs described in this manuscript, which were licensed to Intima Bioscience in December 2021. Licensing revenue is shared with S.S.C. and C.A.K. according to MSKCC institutional policies. MSKCC has filed for patent protection for D.A.S. and M.G.K. for work related to mass spectrometry. C.A.K. has consulted for, or is on the scientific and/or clinical advisory boards for Achilles Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, Bristol Myers Squibb, Catamaran Bio, Cell Design Labs, Decheng Capital, G1 Therapeutics, Klus Pharma, Obsidian Therapeutics, PACT Pharma, Roche/Genentech and T-knife. B.M.B. has previously consulted for Eurkea Therapuetics and is on the scientific advisory board of T-Cure Bioscience. D.A.S. has an equity interest in, consults for or is on the board of Sellas Life Sciences, Pfizer, Oncopep, Actinium, Co-Immune, Eureka, Repertoire, Sapience, Iovance and Arvinas. B.W. reports ad hoc membership of the scientific advisory board of Repare Therapeutics. A.D.C.P. has received honoraria or has served on advisory boards for Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica, mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME and Janssen; Associated Research Paid to Institution from Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho and PharmaMar; Research support from Foundation Medicine; Royalties from Wolters Kluwer; Other from Merck, Puma, Merus and Boehringer Ingelheim; and CME Honoraria from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, EPG Health, JNCC/Harborside, Liberum and Remedica. All other authors declare no competing interests.